Early Discontinuation of Antibiotics in Paediatric High-risk Febrile Neutropenia

Starting soon · Phase 4

Conditions studied: Febrile Neutropenia (FN), Pediatric Cancer, Hematologic Malignancies, Solid Tumors, Invasive Bacterial Infection

In brief

The goal of this clinical trial is to evaluate whether stopping antibiotic treatment early is safe in paediatric patients with cancer who develop high-risk febrile neutropenia but show good clinical evolution and low biomarker levels 48-72 hours after the episode. The main questions it aims to answer are: Is early discontinuation of antibiotics as safe as the standard strategy in terms of preventing invasive bacterial infections (such as sepsis, microbiologically documented infection, ICU admission, or death)? Does this strategy reduce the number of days on antibiotics without increasing infection-related complications? Researchers will compare early antibiotic discontinuation with the standard care strategy to see whether the early-stop approach provides similar safety while reducing antibiotic exposure. Participants will: Receive standard initial antibiotic therapy for febrile neutropenia. Undergo clinical and biomarker evaluations (including CRP and PCT). Be randomly assigned to: Experimental group: early discontinuation of antibiotics, or Control group: continuation of the standard antibiotic strategy. Be followed for 28 days after randomisation to monitor safety outcomes and treatment effects.

Key facts

Study ID: NCT07590648
Run by: Hospital Universitari Vall d'Hebron Research Institute
People needed: 136
Starts: 2026-06-01
Expected to finish: 2028-07-01
Last updated by the study team: 2026-05-15

Who can join

Age: any, up to 18. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Male and female patients ≤18 years of age expected to develop prolonged neutropenia (>7 days), with:
Acute myeloblastic leukaemia at any phase of chemotherapy
Acute lymphoblastic leukaemia in induction, consolidation, or intensification phases
Biphenotypic leukaemia at any phase of chemotherapy
Lymphoblastic lymphoma in induction and consolidation phases
B-cell and anaplastic lymphoma receiving high-intensity chemotherapy
Solid tumours receiving high-intensity chemotherapy
Relapsed leukaemia at any phase of treatment
Episode of febrile neutropenia (FN), defined as a single axillary temperature ≥38.0°C in a patient with an absolute neutrophil count (ANC) <500 neutrophils/mm³, or expected to fall below this value within the next 48-72 hours.
Antibiotic treatment initiated for the current FN episode (routine antimicrobial prophylaxis is allowed, as well as teicoplanin 3 days/week for patients with AML included in the CHIP-AML-2022 protocol and therefore in the Pro-teico study).
Low risk of invasive bacterial infection (IBI) at the start of the FN episode. Patients must meet all of the following:
CRP <9 mg/dL
PCT <0.5 ng/mL
Absence of hypotension
No microbiologically documented bacterial infection 48-72 hours after the FN episode.
Good clinical evolution 48-72 hours after the FN episode, defined as:
Afebrile for >48 hours (axillary temperature <38°C)
Haemodynamically stable
Stable paediatric early warning score (PEWS)
CRP <5 mg/dL, or CRP <9 mg/dL and PCT <0.5 ng/mL, with decreasing trend at the time of randomisation (values will be assessed on day 3 and day 5 after the FN episode).
ANC <500 neutrophils/mm³ at the time of randomisation.
Signed informed consent from the patient and/or parent(s)/legal representative(s).
Patient and/or parent(s)/legal representative(s) must have sufficient reading and writing skills to understand and provide consent to participate in the study.
Patient and/or parent(s)/legal representative(s) must be considered reliable and capable of adhering to the protocol.

You may not qualify if…

Antibiotic treatment at the time of the FN episode different from that used prophylactically.
Empirical antibiotic treatment different from that recommended in international guidelines.
Patient with poor clinical evolution during the first 12 hours (hemodynamic instability, PICU admission, death).
Active participation in the same study at the onset of the current FN episode.
Active participation in another clinical trial that, in the investigators' opinion, may interfere with the assessment of the results.
Any condition which, in the investigator's opinion, makes study participation unsuitable for the patient or could limit, prevent, or confound the assessments planned in the protocol.
Female patients who are pregnant or breastfeeding

Where it is running

Hospital Universitari Vall d'Hebron — Barcelona, Barcelona, Spain
Hospital Sant Joan de Déu — Esplugues de Llobregat, Barcelona, Spain
Hospital Infantil Universitario Niño Jesús — Madrid, Madrid, Spain
Hospital Universitario La Paz — Madrid, Madrid, Spain

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.